Clinical Decision and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning

Sponsor
Ping Liang (Other)
Overall Status
Recruiting
CT.gov ID
NCT05257694
Collaborator
(none)
1
1
48
0

Study Details

Study Description

Brief Summary

Developing a deep learning model based on contrast-enhanced ultrasound (CEUS) to predict the prognosis of hepatocellular carcinoma (HCC) and aid choose operation decisions

Condition or Disease Intervention/Treatment Phase
  • Procedure: Surgery
  • Procedure: Ablation (Microwave ablation or Radiofrequency ablation)

Detailed Description

Collecting CEUS and clinical data of HCC from different institutions retrospectively.

Developing a deep learning model based on CEUS to predict the prognosis of HCC. Developing a deep learning model based on CEUS to choose a better operation (ablation or surgery) of HCC patients.

Then, validating the deep learning model in the prospective data.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Deep Learning Model Based on Contrast-enhanced Ultrasound to Aid Clinical Decisions Prognosis Prediction of Hepatocellular Carcinoma
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Outcome Measures

Primary Outcome Measures

  1. Recurrence-free survival (RFS) [Immediately after the surgery or ablation]

    Recurrence-free survival is defined as the time elapsed between a predefined point in time (the date of diagnosis, randomization or the intervention) and any recurrence (local, regional, or distant) or death due to any cause (death is an event).

Secondary Outcome Measures

  1. Recurrence [Immediately after the surgery or ablation]

    Recurrence included local tumor progression, regional recurrence, or distant recurrence.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with HCC (Ia, Ib, IIa stage) China liver cancer staging who underwent resection or ablation

  • without macro-vascular invasion

  • Child-Pugh A/B grade

  • HCC is proved by pathological examination or two enhanced imaging

  • CEUS (Sonovue or Sonozoid) images are performed two weeks before the operation

  • CEUS images are included in at least three stages (Arterial phase, Portal phase, and Late phase)

Exclusion Criteria:
  • postop follow-up loss or expired less than 3 months

  • patients with co-malignancy

  • poor images quality for analyzing

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chinese PLA General Hospital Beijing Beijing China 100853

Sponsors and Collaborators

  • Ping Liang

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ping Liang, Chief of department of interventional ultrasound, Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT05257694
Other Study ID Numbers:
  • S2022-002
First Posted:
Feb 25, 2022
Last Update Posted:
Mar 16, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2022